Base documentaire
-
Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure.
ARCHIVES OF INTERNAL MEDICINE, vol. 154, n° 10, 1994, pages 1143-1149, 15 réf., ISSN 0003-9926, USA
PAUL (S.D.), KUNTZ (K.M.), EAGLE (K.A.), WEINSTEIN (M.C.)
Massachusetts gen hosp. Dep medicine. Cardiac unit. Boston MA. USA
Background
Chronic heart failure is associated with a poor prognosis and reduced survival rates.
The addition of vasodilator drug therapy to conventional therapy for congestive heart failure has resulted in improved survival.
Methods
Adopting a societal viewpoint, we designed a decision analytic model to analyze the costs and effectiveness of three therapies available for the treatment of congestive heart failure : standard therapy (digoxin and diuretic therapy) plus (1) no vasodilator agents, (2) hydralazine hydrochloride-isosorbide dinitrate combination, and (3) enalapril.
Mots-clés BDSP : Insuffisance cardiaque, Enzyme, Thérapeutique médicamenteuse, Thérapeutique, Homme, Analyse coût efficacité, Economie santé, Appareil circulatoire [pathologie], Cardiopathie
Mots-clés Pascal : Insuffisance cardiaque, Peptidyl-dipeptidase A, Peptidyl-dipeptidases, Proteinases, Hydrolases, Enzyme, Inhibiteur enzyme, Chimiothérapie, Traitement, Vasodilatateur, Homme, Analyse coût efficacité, Economie santé, Appareil circulatoire pathologie, Cardiopathie
Mots-clés Pascal anglais : Heart failure, Peptidyl-dipeptidase A, Peptidyl-dipeptidases, Proteinases, Hydrolases, Enzyme, Enzyme inhibitor, Chemotherapy, Treatment, Vasodilator agent, Human, Cost efficiency analysis, Health economy, Cardiovascular disease, Heart disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et TechniqueCote : 94-0494437
Code Inist : 002B02F04. Création : 199501.
Banque de données en santé publique - http://www.bdsp.ehesp.fr